Related Experiment Video
Updated: May 10, 2026

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
Published on: July 17, 2019
Ras, Raf, and MAP kinase in melanoma
1Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Abstract:
A growing understanding of the biology and molecular mechanisms of melanoma has led to the identification of a number of driver mutations for this aggressive tumor. The most common mutations affect signaling of the Ras/Raf/MAPK (mitogen-activated protein kinase) pathway. This review will focus on mutations in genes encoding proteins that play a role in the MAPK pathway and that have been implicated in melanoma biology, such as BRAF, NRAS, and MEK (MAPK kinase), and detail the current understanding of their role in melanoma progression from a molecular biology perspective. Furthermore, this review will also consider some additional mutations in genes such as KIT, GNAQ, and GNA11, which can be seen in certain subtypes of melanoma and whose gene products interact with the MAPK pathway. In addition, the association of these molecular changes with clinical and classical histopathologic characteristics of melanoma will be outlined and their role in diagnosis of melanocytic lesions discussed. Finally, a basic overview of the current targeted therapy landscape, as far as relevant to the pathologist, will be provided.
Insights
This review details key genetic mutations driving melanoma, focusing on the Ras/Raf/MAPK pathway. Understanding these molecular changes aids in diagnosing melanocytic lesions and developing targeted therapies.
Area of Science:
- Oncology
- Molecular Biology
- Dermatology
Background:
- Melanoma is an aggressive skin cancer with significant molecular heterogeneity.
- Advances in understanding melanoma biology have identified critical driver mutations.
- The Ras/Raf/MAPK pathway is frequently altered in melanoma.
Purpose of the Study:
- To review the molecular biology of melanoma, focusing on key genetic mutations.
- To discuss the role of these mutations in melanoma progression and diagnosis.
- To provide an overview of targeted therapies relevant to pathologists.
Main Methods:
- Literature review of melanoma genetics and molecular mechanisms.
- Focus on mutations in BRAF, NRAS, MEK, KIT, GNAQ, and GNA11.
- Correlation of molecular findings with histopathology and clinical characteristics.
Main Results:
- Common mutations target the Ras/Raf/MAPK pathway (e.g., BRAF, NRAS, MEK).
- Other mutations (e.g., KIT, GNAQ, GNA11) are relevant in specific melanoma subtypes.
- Molecular alterations are associated with clinical and histopathologic features.
Conclusions:
- Understanding melanoma driver mutations is crucial for diagnosis and treatment.
- Targeted therapies are emerging based on specific molecular alterations.
- Pathologists play a key role in integrating molecular data into melanoma management.
More Related Videos
Related Concept Videos
MAPK Signaling Cascades
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway
The Ras Gene
Ras is a superfamily...
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:

